NIH funding notice PAR-23-274

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Closed on November 21, 2024.

Posted: August 23, 2023
Close date: November 21, 2024
Activity codes: UG3, UH3
Institutes taking part: NIA

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page names no earlier notice: it is new, or it does not say.

Replaced by PAR-25-226.

Who won it before

No competing awards from FY2014 to FY2025 name this notice or the notices it replaced.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CV How the NIH biosketch works